Trials to watch: Four biologics concluding pivotal COPD trials
The chronic obstructive pulmonary disorder (COPD) market has laid relatively dormant for the past few years until recently. Several biologics…
The chronic obstructive pulmonary disorder (COPD) market has laid relatively dormant for the past few years until recently. Several biologics…
Armata Pharmaceuticals has completed patient enrollment for its Phase II Tailwind study for inhaled bacteriophage therapy AP-PA02, targeting chronic pulmonary…
US-based Insmed has shared more data from the Phase III ASPEN trial, showing that brensocatib also reduced the decline in…
Insmed’s stocks more than doubled after the company announced its lead-pipeline candidate brensocatib succeeded in a Phase III trial. The…
AstraZeneca and Daiichi Sankyo have reported high-level overall survival (OS) results from the Phase III TROPION-Lung01 clinical trial of datopotamab deruxtecan…
Sanofi has announced positive outcomes from a Phase II clinical trial of rilzabrutinib, an oral treatment for adults with uncontrolled…
GSK has announced positive data from two Phase III trials of its asthma candidate depemokimab. The pharma giant announced the…
Amgen and AstraZeneca have highlighted the potential of Tezspire (tezepelumab) in chronic obstructive pulmonary disease (COPD) in a subgroup of…
Vicore Pharma is looking to move ahead with the Phase IIb trial of its lead pipeline candidate buloxibutid after a…
RAPT Therapeutics has announced plans to terminate two Phase II trials for its lead candidate, zelnecirnon (RPT193), three months after…